Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Funding Programs
Pilot & Feasibility
Conference Support
Summer Student
Collaborative
External Funding Programs
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
FUNDING PROGRAMS
Pilot & Feasibility
Conference Support
Summer Student
Collaborative
External Funding Programs
CONTACT
PARTICIPANT AREA
Login
Request Account
▹
DiaComp Funded Abstracts
Program Application Abstract
Neuroprotective effect of chaperone enhanced aA-crystallin recombinant protein in an in vitro model of diabetic retinopathy
Ameel, Quinn
(University of Michigan-Ann Arbor)
Mentor: Fort, Patrice
Summer Student Program
Diabetic retinopathy (DR) is a common complication of diabetes and is the leading cause of vision loss in the working-age population. While the mechanism remains unclear, retinal ganglion cell (RGCs) death is a well-recognized aspect of DR pathophysiology. Recent studies have pointed to the prosurvival role of aA-crystallin proteins in DR, and its regulation by its phosphorylation on residue 148. To test the hypothesis that aA-crystallin phosphorylation has a neuroprotective role in DR-associated neurodegeneration, primary cells were isolated from double-knockout mice for genes encoding aAcrystallin and aB-crystallin proteins (Ko-CryAA/AB). Wild-type (WT), phosphomimetic (T148D), and nonphosphorylatable (148A) aA-crystallin recombinant proteins were produced. Ko-CryAA/AB primary RGCs were isolated and exposed to diabetes-like conditions made of 100ng/mL TNF-a and 25mmol/L glucose (TNF-a/HG). To investigate the protective potential of A-crystallin recombinant proteins, cell survival and apoptotic rates were assessed in presence or absence of 500ng/mL of either one of the WT, T148A or T148D recombinant proteins. Following treatments, cells were immunohistochemically stained for RNA-binding protein with multiple splicing (RBPMS), a specific RGC cellular marker, along with terminal deoxynucleotide transferase dUTP nick end labeling (TUNEL), which labels DNA breaks to allow visualization of cells undergoing apoptosis. Cells were counted as RBPMS+ cells and RBPMS+/TUNEL+ to demonstrate total RGCs and proportion of these RGCs undergoing apoptosis, respectively. Mean RGC counts were lower in the TNF-a/HG group (58.66) than the control group (95.66), demonstrating diabetes-like milieu induced cell loss. The TNF-/HG/WT condition (87) and TNF- a/HG/148D condition (84.33) showed consistently higher RGC counts in comparison to the TNF- a/HG/148A condition (66.33) and TNF-a/HG condition. Inversely, the mean ratio of RBPMS+/TUNEL+ to only RBPMS+ was highest in TNF-a/HG/148A (0.32), demonstrating the greatest proportion of RGCs undergoing apoptosis. Apoptotic effects were much less significant in TNF-a/HG/WT (0.17) and TNF- a/HG/148D (0.15). These data suggest that phosphorylation on residue 148 of aA-crystallin promotes survival of RGCs in DR, observations consistent with our hypothesis. Due to the nonspecific mechanism of a-crystallin cell protection in the unfolded protein response, these findings have exciting implications for novel treatments of DR and other neurodegenerative diseases with the utilization of exogenous recombinant aA-crystallin proteins.
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an external advisor to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
Internet Explorer
Google Chrome
FireFox
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!